全文获取类型
收费全文 | 263742篇 |
免费 | 15530篇 |
国内免费 | 235篇 |
专业分类
耳鼻咽喉 | 2776篇 |
儿科学 | 7125篇 |
妇产科学 | 8189篇 |
基础医学 | 28672篇 |
口腔科学 | 5764篇 |
临床医学 | 27004篇 |
内科学 | 50520篇 |
皮肤病学 | 5636篇 |
神经病学 | 28416篇 |
特种医学 | 10790篇 |
外科学 | 45534篇 |
综合类 | 1076篇 |
现状与发展 | 2篇 |
一般理论 | 100篇 |
预防医学 | 18910篇 |
眼科学 | 6759篇 |
药学 | 12601篇 |
1篇 | |
中国医学 | 201篇 |
肿瘤学 | 19431篇 |
出版年
2023年 | 5922篇 |
2022年 | 7367篇 |
2021年 | 9639篇 |
2020年 | 9950篇 |
2019年 | 6766篇 |
2018年 | 6951篇 |
2017年 | 6420篇 |
2016年 | 6343篇 |
2015年 | 6263篇 |
2014年 | 12156篇 |
2013年 | 12024篇 |
2012年 | 10260篇 |
2011年 | 10102篇 |
2010年 | 9023篇 |
2009年 | 8242篇 |
2008年 | 8959篇 |
2007年 | 9376篇 |
2006年 | 8877篇 |
2005年 | 8309篇 |
2004年 | 8041篇 |
2003年 | 7992篇 |
2002年 | 7802篇 |
2001年 | 7589篇 |
2000年 | 7706篇 |
1999年 | 6788篇 |
1998年 | 2566篇 |
1997年 | 2095篇 |
1996年 | 2161篇 |
1995年 | 1991篇 |
1994年 | 1730篇 |
1993年 | 1506篇 |
1992年 | 5593篇 |
1991年 | 5557篇 |
1990年 | 5531篇 |
1989年 | 5164篇 |
1988年 | 4832篇 |
1987年 | 2207篇 |
1985年 | 1522篇 |
1984年 | 1745篇 |
1983年 | 1472篇 |
1982年 | 1521篇 |
1981年 | 1503篇 |
1980年 | 1375篇 |
1979年 | 1465篇 |
1978年 | 1332篇 |
1977年 | 1117篇 |
1976年 | 1113篇 |
1975年 | 1057篇 |
1974年 | 1305篇 |
1973年 | 1285篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
53.
54.
《Seminars in arthritis and rheumatism》2021,51(1):84-94
ObjectiveCalcium pyrophosphate crystal deposition disease (CPPD) is a common cause of acute and chronic arthritis, especially in the elderly population. There is a paucity of data regarding the management of CPPD disease, which is currently based on expert opinion and evidence derived from the treatment of gout. We conducted a systematic literature review in order to identify the available treatment options for CPPD, and describe their efficacy and safety.Material and methodsOnline databases were searched from inception to May of 2020 using the search terms: (CPPD [Title/Abstract] OR CPDD [Title/Abstract] OR calcium pyrophosphate [Title/Abstract] OR chondrocalcinosis [Title/Abstract]) AND (treatment [Title/Abstract] OR management [Title/Abstract] OR therapy [Title/Abstract]). Articles evaluating the use of specific treatment agents for CPPD were eligible for inclusion. Case reports were excluded.ResultsA total of 22 eligible studies and 403 unique patients were selected. We identified only 3 randomized, double-blind, controlled trials (RCTs) evaluating the use of methotrexate, hydroxychloroquine, and magnesium carbonate in CPPD, and these therapeutic options, with the exception of methotrexate, have shown efficacy and reduction of pain intensity. Further, 10 case series and 9 cohort studies were included. Intramuscular and intra-articular glucocorticoids, ACTH, as well as the biologic agents anakinra and tocilizumab appear to be efficacious in CPPD. Intra-articular injections of glycosaminoglycan polysulphate, hyaluronic acid and yttrium, as well as synovial membrane destruction by laser irradiation were associated with symptomatic improvement. Due to significant study heterogenicity, direct comparison between studies was not possible.ConclusionThere are a limited number of studies evaluating the treatment of CPPD. High quality evidence is rather limited, while commonly administered agents such as NSAIDs, colchicine and corticosteroids have not been evaluated by RCTs. The need for high quality evidence supporting specific treatment modalities is urgent for this common yet neglected form of arthritis. 相似文献
55.
《Journal of clinical lipidology》2021,15(4):540-544
Cerebrotendinous xanthomatosis (CTX), sitosterolemia, and Smith-Lemli Opitz syndrome (SLOS) are rare inborn errors of metabolism. The diagnoses of CTX and sitosterolemia are often delayed for many years because of lack of physician awareness, often resulting in significant and unnecessary progression of disease. CTX may present with chronic diarrhea, juvenile onset cataracts, strikingly large xanthomas, and neurologic disease in the setting of a normal serum cholesterol, but markedly elevated serum or plasma cholestanol levels. These patients have a defect in producing the bile acid chenodoxycholate, and oral chenodeoxycholate therapy is essential for these patients in order to prevent neurologic complications. Sitosterolemia can present with xanthomas, anemia, thrombocytopenia, splenomegaly, very premature heart disease, and serum cholesterol levels that may be normal or elevated, along with marked elevations of plasma β-sitosterol. These patients have a defect causing overabsorption of β-sitosterol, and the treatment of choice is oral ezetimibe. SLOS presents with growth delay, intellectual disability, multiple structural anomalies, and low serum cholesterol levels, and the defect is reduced cholesterol production. Treatment consists of dietary cholesterol supplementation and oral bile acid therapy which raises serum cholesterol levels and may improve symptoms. The metabolic and genetic defects in these disorders have been defined. There is no one in our field that has contributed more to the diagnosis and treatment of these disorders than Gerald Salen, MD, who died in late 2020 at 85 years of age. He will be greatly missed by his family, friends, and colleagues from around the world. 相似文献
56.
57.
58.
59.
60.